Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study

• Published in: Endokrynologia Polska Vol. 66; no. 2; pp. 142 - 148
• Main Authors: Orlewska, Ewa, Kos-Kudla, Beata, Sowinski, Jerzy, Sworczak, Krzysztof, Zgliczynski, Wojciech
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 2015
• Subjects: Acromegaly - drug therapy; Adolescent; Adult; Aged; Costs; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patients; Peptides, Cyclic - administration & dosage; Peptides, Cyclic - economics; Peptides, Cyclic - therapeutic use; Poland; Prospective Studies; Somatostatin - administration & dosage; Somatostatin - analogs & derivatives; Somatostatin - economics; Somatostatin - therapeutic use; Young Adult; Poland
• ISSN: 0423-104X; 2299-8306
• DOI: 10.5603/EP.2015.0022

To evaluate, over 24 months of prospective follow-up, the dosage and costs of lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland. A multicentre, non-interventional, observational prospective study on resource utilisation in Polish acromegalic patients treated with ATG120 at 4-week or extended (> 4 weeks) dosing interval. The study population consisted of adult acromegalic patients treated for at least 3 injections of ATG120. The endpoints were: percentage of patients treated with ATG120 at an extended dosing interval (> 4 weeks), mean time between injections, and the cost of ATG120 during a 24-month prospective observation. Costs were calculated in PLN from the public health-care payer and patient perspective for the year 2014. 143 patients were enrolled in, and 132 completed (70% women, 81% macroadenoma, 75% previous surgery) the analysis. During two years, changes in the treatment pattern were reported in 41 patients: 17% of them had increased injection interval and 10% switched to octreotide LAR and then returned to ATG120. Sixty-three patients (48%) received ATG120 at an extended dosing interval. ATG120 was predominantly administered in an out-patient setting (84%) by a health care professional (97%). The results demonstrated that extended dosing interval of ATG120 is used in a substantial proportion of patients in routine clinical practice in Poland. Such findings support the potential for ATG120 in reducing treatment burden in the real-world clinical environment.